ENGINEERED ANTI-IL-23P19 ANTIBODIES
First Claim
Patent Images
1. A binding compound that binds to human IL-23p19 comprising:
- a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs;
32-46; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs;
15-31.
3 Assignments
0 Petitions
Accused Products
Abstract
Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.
-
Citations
44 Claims
-
1. A binding compound that binds to human IL-23p19 comprising:
-
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs;
32-46; andb) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs;
15-31. - View Dependent Claims (7, 10)
-
-
2-6. -6. (canceled)
-
8-9. -9. (canceled)
-
11-12. -12. (canceled)
-
13. A binding compound that binds to human IL-23, comprising:
-
a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein; CDRL1 comprises the sequence of SEQ ID NO;
36 or a variant thereof;CDRL2 comprises the sequence of SEQ ID NO;
41 or a variant thereof; andCDRL3 comprises the sequence of SEQ ID NO;
46 or a variant thereof; andb) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein; CDRH1 comprises the sequence of SEQ ID NO;
19 or a variant thereof;CDRH2 comprises a sequence selected from the group consisting of SEQ ID NOs;
24-26 or a variant thereof; andCDRH3 comprises the sequence of SEQ ID NO;
31 or a variant thereof;wherein each variant comprises up to five conservatively modified amino acid substitutions. - View Dependent Claims (14, 19, 43)
-
-
15. A binding compound that binds to human IL-23, comprising:
-
a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein; CDRL1 comprises the sequence of SEQ ID NO;
36;CDRL2 comprises the sequence of SEQ ID NO;
41; andCDRL3 comprises the sequence of SEQ ID NO;
46; andb) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein; CDRH1 comprises the sequence of SEQ ID NO;
19;CDRH2 comprises a sequence selected from the group consisting of SEQ ID NOs;
24-26; andCDRH3 comprises the sequence of SEQ ID NO;
31. - View Dependent Claims (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41)
-
-
16-18. -18. (canceled)
-
20. (canceled)
-
21. A binding compound that binds to human IL-23, comprising:
-
a) an antibody light chain variable domain, or antigen binding fragment thereof, consisting essentially of the sequence of residues 1-108 of SEQ ID NO;
14; andb) an antibody heavy chain variable domain, or antigen binding fragment thereof, consisting essentially of residues 1-116 of a sequence selected from the group consisting of SEQ ID NOs;
6-8. - View Dependent Claims (44)
-
-
22. (canceled)
- 23. A binding compound that binds to human IL-23 at an epitope comprising residues 20-30 or residues 82-110 of SEQ ID NO:
-
26. An antibody, or antigen binding fragment thereof, that is able to block binding of a binding compound comprising:
-
a) an antibody light chain comprising the sequence of SEQ ID NO;
14; andb) an antibody heavy chain comprising a sequence selected from the group consisting of SEQ ID NOs;
6-8,to human IL-23 in a cross-blocking assay.
-
-
40. (canceled)
-
42. (canceled)
-
44-1. An antibody, or antigen binding fragment thereof, that is able to block the binding of human IL-23R to the antibody deposited with ATCC under accession number PTA-7803 in a cross-blocking assay.
Specification